Lensar Inc. (LNSR)
NASDAQ (CM) NASDAQ (CM) Primary Summary
LENSAR Q1 Earnings Call Highlights
LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
Lensar Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 75 | $447 | $433.5 | -$13.5 | -3.02% |
 Charles Brandes Brandes Investment Partners | 1.03M | $7.48M | $5.85M | -$1.63M | -21.77% |
 Joseph Castro Nuveen LLC | 30,061 | $412,875.17 | $174,386.87 | -$238,488.3 | -57.76% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $24 | $22.92 | -$1.08 | -4.5% |
 Christopher C. Powers Farther Finance Advisors, LLC | 101 | $1,420 | $585.8 | -$834.2 | -58.75% |
Lensar Inc. (LNSR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lensar Inc. ever had a stock split?
Lensar Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Nicholas T. Curtis CEO | NASDAQ (CM) Exchange | 52634L108 CUSIP |
| US Country | 150 Employees | - Last Dividend | - Last Split | 2 Oct 2020 IPO Date |
Overview
LENSAR, Inc. is a commercial-stage medical device company with a focus on the innovative application of femtosecond laser technology for the treatment of cataracts and the correction of corneal astigmatism. Established in 2004 and based in Orlando, Florida, LENSAR has dedicated itself to enhancing the precision, efficiency, and outcomes of cataract surgery through its advanced laser systems. The company positions itself at the forefront of ophthalmic surgery by providing solutions designed to improve visual outcomes and offer reproducible procedures to surgeons. Through continuous technological advancements, LENSAR strives to meet the evolving needs of both surgeons and patients in the field of eye surgery.
Products and Services
- LENSAR Laser System
This flagship product by LENSAR, Inc. embodies a suite of proprietary technologies tailored to assist surgeons in achieving superior visual outcomes, operational efficiency, and consistency in procedures. The LENSAR Laser System leverages advanced imaging and precision planning tools to facilitate the treatment of cataracts and corneal astigmatism. By incorporating procedure planning, design, and execution functionalities, this laser system empowers surgeons to perform surgeries with heightened precision and patient-specific customization, ultimately aiming to enhance the quality of life for patients through improved vision.
- ALLY Adaptive Cataract Treatment System
The ALLY Adaptive Cataract Treatment System represents a significant advancement in femtosecond laser technology, offering features that consolidate enhanced laser capabilities within a compact unit. Designed for versatility and efficiency, the ALLY system allows for the integration of femtosecond laser-assisted cataract procedures into a single operating room setup, streamlining the surgical process. This innovation not only improves the surgical workflow but also enables surgeons to deliver more precise and customizable treatments, furthering LENSAR's mission to advance surgical outcomes and patient satisfaction in cataract surgery.
